Gilead Sciences Inc. (GILD, Financial), CVS Health Corp. (CVS, Financial), Macerich Co. (MAC, Financial) and OPKO Health Inc. (OPK, Financial) have declined to their three-year lows.
Gilead Sciences Inc. (GILD, Financial) declined to $62.95
The prices of Gilead Sciences Inc. (GILD, Financial) shares have declined to $62.95 on April 19, which is only 4.2% above the three-year low of $60.32.
Gilead Sciences Inc. is an American international pharmaceutical and biotechnology company that develops and commercializes therapeutics. The company focuses primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C and influenza. Some of the products that the company developed include AmBisome, Atripla, Cayston, Emtriva and Flolan.
Gilead Sciences Inc. has a market cap of $80.25 billion; its shares were traded around $62.95 with a price-earnings ratio of 15.13 and price-sales ratio of 3.72. The trailing 12-month dividend yield of Gilead Sciences Inc. stocks is 3.72%. The forward dividend yield of Gilead Sciences Inc. stocks is 4%. Gilead Sciences Inc. had an annual average earnings growth of 26.10% over the past 10 years.
On April 12 Gilead Sciences Inc. announced that it intends to collaborate with Novo Nordisk A/S on a clinical trial that combines compounds from their respective pipelines in nonalcoholic steatohepatitis. The intended clinical trial will be a proof of concept study combing Novo Nordisk’s semaglutide and Gilead’s cilofexor for the treatment of patients with NASH.
CVS Health Corp. (CVS, Financial) declined to $52.63
The prices of CVS Health Corp. (CVS, Financial) shares have declined to $52.63 on April 19, which is only 1.6% above the three-year low of $51.77.
CVS Health Corp. is an American retail pharmacy and health care company that grew from the parent company Mark Steven Inc. The business began as a chain of health and beauty aid stores but within several years pharmacies were added. The company owns several subsidiaries, including CVS Pharmacy, MinuteClinic, Caremark Rx, Longs Drugs, Omnicare and Navarro Discount Pharmacies.
CVS Health Corp. has a market cap of $68.34 billion; its shares were traded around $52.63 with a price-sales ratio of 0.28. The trailing 12-month dividend yield of CVS Health Corp. stocks is 3.80%. The forward dividend yield of CVS Health Corp. stocks is 3.80%. CVS Health Corp. had an annual average earnings growth of 7.40% over the past 10 years.
On April 4, CVS Health Corp. announced that it has completed the rollout of time delay safes in all its 169 pharmacy locations in Tennessee. The safes will help prevent pharmacy robberies to combat the opioid epidemic in the state. These measures will help keep controlled substance narcotic medications out of the possession of unauthorized individuals.
Macerich Co. (MAC, Financial) declined to $41.46
The prices of Macerich Co. (MAC, Financial) shares have declined to $41.46 on April 19, which is only 3.4% above the three-year low of $40.03.
Macerich Co. is an American self-managed real estate investment trust. It is the third-largest owner and operator of shopping centers in the United States and is a component of the S&P 500. The company owns property across the U.S., including property in California, Arizona, Washington, Missouri and New York.
Macerich Co. has a market cap of $5.85 billion; its shares were traded around $41.46 with a price-earnings ratio of 101.12 and price-sales ratio of 6.09. The trailing 12-month dividend yield of Macerich Co. stocks is 7.19%. The forward dividend yield of Macerich Co. stocks is 7.24%.
On Feb. 7, Macerich Co. announced financial results for the quarter ended on Dec. 31, 2018. Net income for the quarter was $11.7 million or 8 cents per diluted share, compared to net income of $32.8 million or 23 cents per diluted share during the same quarter prior year. Funds from operations was $165.7 million or $1.09 per diluted share for the quarter compared to funds from operations of $155.6 million or $1.03 per diluted share during the same quarter prior year.
OPKO Health Inc. (OPK, Financial) declined to $2.40
The prices of OPKO Health Inc. (OPK, Financial) shares have declined to $2.40 on April 19, which is only 2.5% above the three-year low of $2.34.
OPKO Health Inc. is an American pharmaceutical and medical test company. The company is mainly focused on diagnostics and pharmaceuticals, but also develops treatments for secondary hyperparathyroidism. In 2014, it acquired Laboratorio Arama de Uruguay.
OPKO Health Inc. has a market cap of $1.48 billion; its shares were traded around $2.40 with a price-sales ratio of 1.34.
On March 21 OPKO Health Inc. announced positive topline results from a Phase 2 dose escalation trial of POK 88003 to treat type 2 diabetes and obesity. The drug is a once weekly injectable oxyntomodulin compound. An optimized dosing regimen for the drug was evaluated based on data from a previous 420 patient Phase 2 study to improve glucose control and increase weight loss.
Disclosure: I do not own stock in any of the companies mentioned.
